Literature DB >> 21900102

European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation.

David Marin, Amr R Ibrahim, John M Goldman.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21900102     DOI： 10.1200/JCO.2011.37.6962

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  22 in total

1.  EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.

Authors:  Elias Jabbour; Jorge Cortes; Aziz Nazha; Susan O'Brien; Alfonso Quintas-Cardama; Sherry Pierce; Guillermo Garcia-Manero; Hagop Kantarjian
Journal:  Blood       Date:  2012-03-19       Impact factor: 22.113

2.  Performance of Sokal and Eutos Scores for Predicting Cytogenetic and Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients on Imatinib.

Authors:  Sandip Ganguly; K C Lakshmaiah; Linu Abraham Jacob; Suresh Babu; Lokanatha Dasappa; K S Govind Babu
Journal:  Indian J Hematol Blood Transfus       Date:  2016-03-14       Impact factor: 0.900

Review 3.  The role of observational studies in optimizing the clinical management of chronic myeloid leukemia.

Authors:  Michael J Mauro; Catherine Davis; Teresa Zyczynski; H Jean Khoury
Journal:  Ther Adv Hematol       Date:  2015-02

Review 4.  Re-defining Prognosis of Hematological Malignancies by Dynamic Response Assessment Methods: Lessons Learnt in Chronic Myeloid Leukemia, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma and Multiple Myeloma.

Authors:  Arihant Jain; Ankur Jain; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2019-10-22       Impact factor: 0.900

5.  Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib.

Authors:  Chung H Kok; David T Yeung; Liu Lu; Dale B Watkins; Tamara M Leclercq; Phuong Dang; Verity A Saunders; John Reynolds; Deborah L White; Timothy P Hughes
Journal:  Blood Adv       Date:  2019-05-28

Review 6.  Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.

Authors:  Elias J Jabbour; Timothy P Hughes; Jorge E Cortés; Hagop M Kantarjian; Andreas Hochhaus
Journal:  Leuk Lymphoma       Date:  2013-11-12

7.  Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib.

Authors:  Jose Francis; Biswajit Dubashi; Rajan Sundaram; Suresh Chandra Pradhan; Adithan Chandrasekaran
Journal:  Med Oncol       Date:  2015-07-05       Impact factor: 3.064

8.  Biology of CML stem cells: the basis for clinical heterogeneity?

Authors:  J M Goldman; M Gordon; A Bazeos; D Marin
Journal:  Leuk Suppl       Date:  2012-08-09

9.  Improved prediction of clinical outcome in chronic myeloid leukemia.

Authors:  Irena Ćojbašić; Lana Mačukanović-Golubović; Dragan Mihailović; Miodrag Vučić; Stevo Lukić
Journal:  Int J Hematol       Date:  2014-12-25       Impact factor: 2.490

10.  Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population.

Authors:  Seung-Ah Yahng; Eun-Jung Jang; Soo-Young Choi; Sung-Eun Lee; Soo-Hyun Kim; Dong-Wook Kim
Journal:  Int J Hematol       Date:  2014-05-31       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.